Status:
UNKNOWN
Bridging ED to Outpatient AUD Therapy With Naltrexone
Lead Sponsor:
Albert Einstein Healthcare Network
Conditions:
Alcohol Use Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Alcohol use disorder (AUD) is a treatable and common condition encountered in the emergency department, but unfortunately is rarely directly addressed in emergency departments nationwide. To our knowl...
Detailed Description
The burden of excessive alcohol use in Pennsylvania is significant. In 2013, the CDC estimated that excessive alcohol use caused about 3,510 deaths per year in Pennsylvania and cost an estimated $8.3 ...
Eligibility Criteria
Inclusion
- 18 years of age or older
- Presents to the ED with chief complaint of alcohol use or judged to have alcohol use as a significant contributing factor to their presentation to the emergency department
- Patients must be interested in reducing or stopping their alcohol use
- AUDIT score greater or equal to 16
Exclusion
- Patients will be excluded if they previously participated in the study
- patients who will be admitted to the hospital
- Endorse dependence on opioid medications or opioid street drugs
- have an extended urine drug screen that is positive for opioids
- elevated liver transaminase (AST or ALT) that is greater than 5 times the upper limit of normal
- decompensated liver disease
- allergic reaction to naltrexone
- pregnant
- prisoners
- unable to provide consent
- subjects in police custody
- non-English speaking
- have no reliable means for future contact.
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05228418
Start Date
March 1 2022
End Date
July 1 2025
Last Update
February 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Albert Einstein Medical Center Philadelphia
Philadelphia, Pennsylvania, United States, 19141